Advice
in the absence of a submission from the holder of the marketing authorisation:
gefapixant (Lyfnua®) is not recommended for use within NHSScotland.
Indication under review: in adults for the treatment of refractory or unexplained chronic cough.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice372KB (PDF)
Medicine details
- Medicine name:
- gefapixant (Lyfnua)
- SMC ID:
- SMC2926
- Indication:
In adults for the treatment of refractory or unexplained chronic cough.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 May 2026